Clinical Trial Update: 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study [Phase 3]

View source ↗

Summary

Phase 3 ZIRCON trial evaluating the PET/CT imaging agent 89Zr-TLX250 for clear cell renal cell carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• 89Zr-TLX250 (89Zr-TLX250)

Snippet

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited | Conditions: Clear Cell Renal Cell Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2024-05-17